Allergan plc Ordinary Shares (AGN) was Initiated by Guggenheim to “Neutral”. Guggenheim advised their investors in a research report released on Apr 18, 2016.
Many Wall Street Analysts have commented on Allergan plc Ordinary Shares. Shares were Downgraded by Piper Jaffray on Apr 18, 2016 to ” Neutral” and Lowered the Price Target to $ 238 from a previous price target of $311 .Morgan Stanley Resumed Allergan plc Ordinary Shares on Apr 7, 2016 to “Overweight”, Price Target of the shares are set at $300.Shares were Reiterated by UBS on Apr 7, 2016 to “Buy” and Lowered the Price Target to $ 300 from a previous price target of $366 .
On the company’s financial health, Allergan plc Ordinary Shares reported $3.41 EPS for the quarter, beating the analyst consensus estimate by $ 0.09 according to the earnings call on Feb 22, 2016. Analyst had a consensus of $3.32. The company had revenue of $4197.50 million for the quarter, compared to analysts expectations of $4179.62 million. The company’s revenue was up 73.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.57 EPS.
Allergan plc Ordinary Shares opened for trading at $217.56 and hit $220.65 on the upside on Friday, eventually ending the session at $217.16, with a gain of 0.36% or 0.77 points. The heightened volatility saw the trading volume jump to 51,86,971 shares. Company has a market cap of $85,710 M.
In a different news, on Dec 9, 2015, Nesli Basgoz (director) sold 2,300 shares at $312.96 per share price. According to the SEC, on Aug 24, 2015, Brent L Saunders (CEO) purchased 1,000 shares at $301.94 per share price. On Aug 24, 2015, Paul Bisaro (Exec Chairman) purchased 1,000 shares at $297.42 per share price, according to the Form-4 filing with the securities and exchange commission.